神经分泌生物科学
NBIX
135.71
-1.24
-0.91%
神经分泌生物科学
US · NBIX
#1162 按市值排名
上市于 1970
135.71
-1.24
-0.91%
实时 - 追踪5344个代码 - 心跳于25秒前
· 2026-10-16 19:30
✦ 量化股权信号 计算方式说明
减持
- 最近一期（2026/Q3）披露持股的机构数量减少了5家。
- 机构持股总比例下降了1.7个百分点。
机构持股
- 机构持股比例
- 101.68% -1.71pp
- 机构数量
- 939 -5
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向一致机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向一致。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund76.50%
Hedge Fund15.49%
Public Company3.47%
Government Pension Fund2.92%
Private Company1.43%
Individual/Insider1.18%
Sovereign Wealth Fund1.14%
Insurance Company0.35%
Family Office/Trust0.17%
主要股东 截至 2026-06-30
BlackRock
13.49% · 13.71M 股
J.P. Morgan Asset Management, Inc.
5.92% · 6.02M 股
Dodge & Cox
5.49% · 5.58M 股
Vanguard Capital Management, LLC
5.11% · 5.19M 股
Vanguard Portfolio Management, LLC
4.89% · 4.97M 股
State Street Global Advisors
4.31% · 4.39M 股
AQR Capital Management
3.72% · 3.78M 股
Renaissance Technologies Corp.
2.30% · 2.34M 股
Geode Capital Management, LLC
2.10% · 2.14M 股
Two Sigma Investments, LP
2.04% · 2.08M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 20次买入 · 30次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Kevin Gorman | Chief Executive Officer | 0.51% |
| Kyle Gano | Chief Business Development and Strategy Officer | 0.15% |
| Gary Lyons | Independent Director | 0.12% |
| Eric Benevich | Chief Commercial Officer | 0.07% |
| Darin Lippoldt | Chief Legal Officer | 0.06% |
| William Rastetter | Independent Chairperson | 0.04% |
| Matthew Abernethy | Chief Financial Officer | 0.04% |
| Richard Pops | Independent Director | 0.04% |
| Eiry Roberts | Chief Medical Officer | 0.04% |
| Julie Cooke | Chief Human Resources Officer | 0.02% |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-09-13 | Matthew Abernethy | Chief Financial Officer | Automatic Disposition | -2,311 | $157.20 |
| 2026-09-13 | David Boyer | Chief Corporate Affairs Officer | Automatic Disposition | -826 | $157.45 |
| 2026-09-10 | Kevin Gorman | Chief Executive Officer | Sale to Issuer | -7,839 | $156.22 |
| 2026-09-10 | Kevin Gorman | Chief Executive Officer | Other Acquisition | +14,343 | -- |
| 2026-09-10 | Julie Cooke | Chief Human Resources Officer | Sale to Issuer | -1,936 | $156.22 |
| 2026-09-10 | Julie Cooke | Chief Human Resources Officer | Other Acquisition | +3,587 | -- |
| 2026-09-10 | Eric Benevich | Chief Commercial Officer | Sale to Issuer | -3,386 | $156.22 |
| 2026-09-10 | Eric Benevich | Chief Commercial Officer | Other Acquisition | +6,275 | -- |
| 2026-09-10 | Jude Onyia | Chief Scientific Officer | Sale to Issuer | -1,936 | $156.22 |
| 2026-09-10 | Jude Onyia | Chief Scientific Officer | Other Acquisition | +3,587 | -- |
| 2026-09-10 | Darin Lippoldt | Chief Legal Officer | Sale to Issuer | -2,419 | $156.22 |
| 2026-09-10 | Darin Lippoldt | Chief Legal Officer | Other Acquisition | +4,483 | -- |
| 2026-09-10 | Kyle Gano | Chief Business Development and Strategy Officer | Sale to Issuer | -4,380 | $156.22 |
| 2026-09-10 | Kyle Gano | Chief Business Development and Strategy Officer | Other Acquisition | +8,117 | -- |
| 2026-09-10 | Matthew Abernethy | Chief Financial Officer | Sale to Issuer | -2,709 | $156.22 |
| 2026-09-10 | Matthew Abernethy | Chief Financial Officer | Other Acquisition | +5,020 | -- |
| 2026-09-10 | David Boyer | Chief Corporate Affairs Officer | Sale to Issuer | -1,936 | $156.22 |
| 2026-09-10 | David Boyer | Chief Corporate Affairs Officer | Other Acquisition | +3,587 | -- |
| 2026-09-10 | Sanjay Keswani | Chief Medical Officer | Sale to Issuer | -2,112 | $156.22 |
| 2026-09-10 | Sanjay Keswani | Chief Medical Officer | Other Acquisition | +3,914 | -- |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:30:04 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
神经分泌生物科学 讨论区 0 条评论